MyCME, the leader in free medical education, offers a host of courses across all cardiovascular diseases. Access the entire library of Cardiology CME and CE for free.
The top cardiology CME courses available now on www.myCME.com include topics on mitral stenosis, anemia, cardiac arrhythmia, and more.
Program Description
Moderated by James A. Underberg, MD, MS, FACP, FNLA and featuring a panel with four faculty speakers (Linda Hemphill, MD, FACC, FNLA, FAHA, Robert Rosenson, MD, Seth Martin, MD, MHS, and Luba Burchett, RN, BSN) this 60 minute webcast will cover the following information: epidemiology of homozygous familial hypercholesterolemia (HoFH), signs and symptoms, diagnosis and identification of patients with HoFH, screening and genetic tests, currently available treatment options for patients, current guidelines for treatment, experience with evinacumab, navigating the treatment of women and children, and potential barriers to treatment.
Educational Objectives
Upon completion, participants should be able to:
- Identify the signs, symptoms, and diagnostic markers of familial hypercholesterolemia
- Describe current guidelines for the treatment of homozygous familial hypercholesterolemia (HoFH)
- Compare and contrast current treatment options for HoFH
- Formulate care strategies that incorporate patient needs and potential barriers to treatment
Intended Audience
Cardiologists, lipidologists, internists, primary care providers, infusion center nurses, and other healthcare providers who treat patients with HoFH.
Commercial Supporter
This activity is supported by an educational grant from Regeneron Pharmaceuticals.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / ANCC Contact Hour
Expires: April 14, 2023
Program Description
Dr. Tsuyoshi Kaneko lends an expert perspective on the rapidly growing evidence base on the role of transcatheter aortic valve replacement (TAVR) in patients with bicuspid valve anatomy, including the most recent data presented at the 2022 annual meeting of the Society of Thoracic Surgeons (STS). While outcomes can rival those seen with traditional surgical valve replacement, Dr. Kaneko notes important caveats regarding proper patient selection that underscore the need for assessment by a heart valve team when deciding between the two approaches.
Educational Objectives
Upon completion, participants should be able to:
- Summarize the findings of recent data registry analyses in patients with bicuspid aortic valves who have undergone either surgical or transcatheter aortic valve replacement (SAVR or TAVR)
- Apply these data to the identification of patients with bicuspid valve anatomy who would benefit from evaluation by a heart valve team
Intended Audience
The target audience for this activity is members of the heart valve team, including referring/community cardiologists, interventional cardiologists, and cardiothoracic surgeons, as well as primary care physicians, nurses, nurse practitioners, physician associates, and others who care for patients with aortic stenosis and bicuspid anatomy.
Commercial Supporter
Supported by an educational grant from Edwards Lifesciences.
Max Credits
- 0.50 / AMA PRA Category 1 Credit(s)
- 0.50 / ANCC Contact Hour(s)
Expires: April 15, 2023
Program Description
Hypertrophic cardiomyopathy (HCM) is an under-recognized, common, and treatable genetic disease occurring worldwide. HCM is a myocardial disorder most often caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus of the heart. It is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Adding to the burden of disease, HCM can present with a variety of symptoms mimicking other conditions and may go undiagnosed for many years and it is estimated that approximately one in 500 individuals in the United States may have clinically unrecognized, undiagnosed HCM, with an overall prevalence estimated at 750,000.
Please join Dr. Maron and Dr. Torres in this first installment of a CMEO Snack series as they discuss strategies for optimal screening of HCM in an effort to increase recognition and diagnosis of this too often misdiagnosed disease.
Educational Objectives
Upon completion, participants should be able to:
- Assess safety and efficacy of emerging agents.
Intended Audience
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists).
Commercial Supporter
Supported by an educational grant from Bristol Myers Squibb.
Max Credits
- 0.50 / AMA PRA Category 1 Credit
- 0.50 / ABIM MOC Point
- 0.50 / AAPA Category 1 CME Credit
- 0.50 / ANCC Contact Hour
- 0.50 / CE for Pharmacists
Expires: May 10, 2023
Program Description
Hypertrophic cardiomyopathy (HCM) can be a chronic, progressive condition in which patients experience symptoms of dyspnea, dizziness, and fatigue as well as serious complications such as heart failure, arrhythmias, stroke, and sudden cardiac death. HCM is a masquerading disease and is easily confused with other conditions. Because there are many different symptomatic manifestations of HCM, clinicians are not always up to date with evidence-based treatment recommendations, missing opportunities to provide relief to patients with HCM. Practice guidelines for HCM released in December 2020 by the AHA/ACC provide further detail on when to use available treatment options. Clinicians need to stay current on the latest recommendations to prepare to treat or refer patients with HCM to a specialist.
Join Drs. Maron and Olivotto in this 2nd installment of a 3-part CMEO Snack series on HCM as they identify strategies for clinicians to better implement global and country-specific guideline recommendations to improve care for patients with HCM.
Educational Objectives
Upon completion, participants should be able to:
- Assess safety and efficacy of emerging agents.
Intended Audience
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists).
Commercial Supporter
Supported by an educational grant from Bristol Myers Squibb.
Max Credits
- 0.50 / AMA PRA Category 1 Credit
- 0.50 / ABIM MOC Point
- 0.50 / AAPA Category 1 CME Credit
- 0.50 / ANCC Contact Hour
- 0.50 / CE for Pharmacists
Expires: May 10, 2023
Program Description
Hypertrophic cardiomyopathy (HCM) is prevalent around the world, with a conservatively estimated 20 million individuals affected. Even in developed countries, current management of HCM is suboptimal. Much has been learned over the past 2 decades about the pathophysiology of HCM and new therapies such as mavacamten, CK-274, IMB-101, and CT-G20 are currently being developed and tested in clinical trials addressing the underlying pathophysiology of HCM. Although these new agents are in late stages of development, clinicians are often not fully up to date on this progress and the potential opportunity to improve care for patients.
Please join Drs. Maron and Rakowski in this final installment of a CMEO Snack series on HCM as they discuss methods to assess study results of emerging HCM disease-specific treatments targeting cardiac myosin in order to optimize outcomes for patients.
Educational Objectives
Upon completion, participants should be able to:
- Assess study results of emerging HCM disease-specific treatments regarding cardiac myosin.
Intended Audience
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists).
Commercial Supporter
Supported by an educational grant from Bristol Myers Squibb.
Max Credits
- 0.50 / AMA PRA Category 1 Credit
- 0.50 / ABIM MOC Point
- 0.50 / AAPA Category 1 CME Credit
- 0.50 / ANCC Contact Hour
- 0.50 / CE for Pharmacists
Expires: May 10, 2023
Program Description
Treatment guidelines include recommendations on recently approved medications and discussions of recent clinical trial data on monotherapy and combination treatment options for pulmonary arterial hypertension (PAH). Current and emerging management strategies target new pathways and treatment targets. This foundational activity provides nurses with a high-level overview of treatment pathways and therapeutic targets for the management of PAH.
Educational Objectives
Upon completion, participants should be able to:
- Review the pathophysiology, diagnostic criteria, and classification of PAH.
- Identify the classes and associated side effects of medications used to treat PAH.
- Summarize new treatment pathways and emerging therapeutic targets in the management of PAH.
- Recognize the potential for remote monitoring via telehealth in patients with PAH.
Intended Audience
The intended audience includes nurse practitioners, nurses, physician assistants and other providers involved in the management of patients with PAH.
Commercial Supporter
This activity is supported by an independent medical education grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Max Credits
- 1.00 / AAPA Category 1 CME Credit
- 1.00 / AANP Contact Hour
- 1.00 / ANCC Contact Hour
Expires: May 14, 2023
Program Description
In this GapEd Webcast, expert faculty speakers Naushira Pandya and Meenakshi Patel will illustrate through patient cases the importance of individualized A1C goals and strategies on how to optimize glycemic control while simplifying regimens, minimizing hypoglycemia risk, and improving interdisciplinary communication. Through this gap-based activity, learners will be able to skip content they know well and view content that is consider essential by the faculty, or they have a demonstrated gap in knowledge.
Educational Objectives
Upon completion, participants should be able to:
- Individualize A1C goals based on patient- and disease-specific factors
- Compare and contrast fix-ratio combinations of GLP-1 RA plus basal insulin with other insulin regimens
- Devise glucose lowering regimens that optimizes quality of life and glucose control and minimizes hypoglycemia
- Implement strategies to improve interdisciplinary communication and facility care processes to optimize diabetes outcomes
Intended Audience
Primary Care Physicians, Diabetologists, Endocrinologists, Family Practice Physicians, Family Practice/General Practice Physicians, General Practice Physicians, Geriatric Medicine Physicians, Internal Medicine Physicians, Managed Care, Nurse Practitioners, Physician Assistants, Other healthcare professionals who treat patients with diabetes in a long-term care facility
Commercial Supporter
This activity is supported by an educational grant from Sanofi US.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
Expires: May 15, 2023
Program Description
Dr. Gregory Serrao from Mount Sinai discusses antiplatelet concerns and pharmacodynamics in the context of cardiogenic shock. Next, review the trial data, indications, and contraindications on cangrelor presented by Dr. Jennifer Rymer, MD, from Duke Health. Furthermore, you will understand the optimal “recipe” for antiplatelet management in HR NSTEMI, STEMI, and cardiogenic shock. Finally, view a case focused on antiplatelet therapy with cardiogenic shock.
Educational Objectives
Upon completion, participants should be able to:
- Examine the pharmacokinetic/pharmacodynamic profile of parenteral antiplatelet agents
- Review current data on antiplatelet considerations in acute coronary syndrome (ACS) and cardiogenic shock
- Describe contemporary antiplatelet treatment protocols in ST-elevation myocardial infarction (STEMI) and cardiogenic shock
- Discuss future antiplatelet and antithrombotic therapeutic targets
Intended Audience
Cardiologists
Commercial Supporter
This activity is supported by an unrestricted educational grant from Chiesi.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / ABIM MOC Point
Expires: May 30, 2023
Program Description
Review Right-Sided mechanical circulatory support (MCS) with RA-PA Pump and Left-Sided MCS with LA-AO Pump. Learn more about the emerging role of VA ECMO in the cath lab from Dr. Emmanouil Brilakis. Discuss an overview of biventricular MCS with LA-AO and RA-PA pumps from Dr. Khaldoon Alaswad with Henry Ford Health and apply the information with a case presentation. Dr. Daniel Burkhoff from CRF and Dr. Rajan Patel moderate a lively discussion.
Educational Objectives
Upon completion, participants should be able to:
- Assess the implications of right ventricular (RV) failure in cardiogenic shock
- Discuss the benefits of left atrial-aorta (LA-AO) and right atrial-pulmonary artery (RA-PA) MCS systems
- Describe the role of biventricular MCS in treating cardiogenic shock
Intended Audience
Cardiologists, Emergency Care Physicians, Hospitalists
Commercial Supporter
This activity is supported by an educational grant from LivaNova.
Max Credits
- 1.00 / AMA PRA Category 1 Credit
- 1.00 / ABIM MOC Point
Expires: May 30, 2023
Program Description
Light chain (AL) amyloidosis, a rare clonal plasma cell disorder characterized by organ deposition of amyloid protein, results in progressive organ damage that is usually irreversible. Prompt treatment is critical to achieving the best possible outcomes, but rapid initiation of treatment requires early, accurate diagnosis, which is often delayed because of the nonspecific nature of the symptoms. Unfortunately, delayed diagnosis is a grave concern, as the median survival rate among some untreated patients is approximately 6 months following symptom onset.
A high index of suspicion and appropriate testing are needed to make a diagnosis of AL amyloidosis, but the significant delays and multiple physician visits patients typically encounter (many patients report seeing at least five physicians, including cardiologists and nephrologists, before receiving a diagnosis) indicate that clinicians continue to be confounded by this condition’s highly variable clinical presentation.
Therapies for AL amyloidosis target the aberrant plasma/B-cell clone and have traditionally been based on regimens adapted from the expanding treatment options available for multiple myeloma; however, in January 2021 the FDA approved a therapy specifically for use in patients with AL amyloidosis.
This activity features a roundtable discussion with a multidisciplinary panel of experts on the latest information on evidence-based diagnosis and treatment guidelines for patients with AL amyloidosis.
Educational Objectives
Upon completion, participants should be able to:
- Recognize the clinical presentations that should raise suspicion of AL amyloidosis
- Utilize optimal diagnostic testing to minimize delays in treatment initiation
- Outline current and emerging treatment options that are available to treat patients with AL amyloidosis, using supporting clinical trial data
Intended Audience
This activity is designed to meet the educational needs of hematologist-oncologists, medical oncologists, oncology nurses, cardiologists, nephrologists, and other health care providers involved in the diagnosis and treatment of patients with AL amyloidosis.
Commercial Supporter
This activity is supported by educational grants from The Binding Site and Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC.
Max Credits
- 1.00 / AMA PRA Category 1 Credit(s)
- 1.00 / ABIM MOC Part II Points
- 1.00 / CNE Contact Hour(s)
Expires: June 6, 2023
The Cardiology Advisor Institute, powered by myCme, is a specialty-based community offering cardiology CE and CME courses, resources, and news tailored and curated for you. Specialized topics include these and more:
- Homozygous familial hypercholesterolemia (HoFH)
- Mineralocorticoid receptor antagonists
- Hypertrophic cardiomyopathy (HCM)
- Atrial fibrillation and AFIB treatment
- High-sensitivity cardiac troponin (hs-cTn)
- Transcatheter aortic valve replacement (TAVR)
Make sure to take advantage of this catalog of accredited free cardiology CE and CME courses for your continuing education.
